Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | WNK1 | Q9H4A3 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1015486 | 1.00 | HCAR3 (0.53) | HCAR3DRD2ALDH1A1NPC1WNK1 | |
| SCHEMBL1018158 | 0.94 | HCAR3 (0.48) | HCAR3DRD2ALDH1A1NPC1WNK1 | |
| SCHEMBL1018156 | 0.94 | HCAR3 (0.48) | HCAR3DRD2ALDH1A1NPC1WNK1 | |
| SCHEMBL1018157 | 0.94 | HCAR3 (0.48) | HCAR3DRD2ALDH1A1NPC1WNK1 | |
| SCHEMBL15599592 | 0.88 | HCAR3 (0.52) | HCAR3DRD2ALDH1A1NPC1WNK1 | |
| SCHEMBL16989691 | 0.88 | HCAR3 (0.52) | HCAR3DRD2ALDH1A1NPC1WNK1 | |
| SCHEMBL18687361 | 0.86 | HCAR3 (0.50) | HCAR3DRD2ALDH1A1NPC1WNK1 | |
| SCHEMBL7183491 | 0.86 | PKM (0.55) | HCAR3ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL7183476 | 0.86 | PKM (0.55) | HCAR3ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL7177008 | 0.85 | HCAR3 (0.49) | HCAR3DRD2KDM1AMAOBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2089368-B1 | DIAMINOCYCLOHEXANE AND DIAMINOCYCLOPENTANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-7652053-B2 | Diaminocycloalkane MCH receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20080146636-A1 | For therapy of obesity, hyperphagia, anxiety, depression and related disorders and diseases; cis-(S)-2-(1-{4-[(5-Bromo-indan-2-ylmethyl)-amino]-cyclohexyl}-5-chloro-1H-benzoimidazol-2-yl)-propan-2-ol | ERICKSON SHAWN DAVID | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146636-A1 | For therapy of obesity, hyperphagia, anxiety, depression and related disorders and diseases; cis-(S)-2-(1-{4-[(5-Bromo-indan-2-ylmethyl)-amino]-cyclohexyl}-5-chloro-1H-benzoimidazol-2-yl)-propan-2-ol | GPR119, GIPR, EBP | HCAR3 1299/4885DRD2 330/4885ALDH1A1 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.